To translate this concept into a future use in patients, we developed and in vitro-validated a series of ASOs that induce the efficient skipping of the target exons from pre-mRNA, therewith offering an excellent basis for the further development of a dual exon skipping therapy for patients suffering from RP caused by mutations in USH2A exons 30, 31, 39, or 40. Here, USH2A is linked to retinitis pigmentosa 1.